OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 22.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 179,266 shares of the company's stock after buying an additional 32,329 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC's holdings in Roivant Sciences were worth $2,121,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Russell Investments Group Ltd. grew its stake in shares of Roivant Sciences by 478.6% during the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after acquiring an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd bought a new position in shares of Roivant Sciences during the 4th quarter valued at approximately $39,000. GAMMA Investing LLC grew its stake in shares of Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock valued at $42,000 after acquiring an additional 1,288 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after acquiring an additional 1,507 shares during the period. Finally, Wells Fargo & Company MN grew its stake in shares of Roivant Sciences by 84.1% during the 4th quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock valued at $89,000 after acquiring an additional 3,426 shares during the period. Institutional investors own 64.76% of the company's stock.

Insider Activity

In related news, major shareholder Vivek Ramaswamy sold 273,959 shares of the stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the sale, the insider now owns 39,799,611 shares in the company, valued at approximately $456,501,538.17. This represents a 0.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Eric Venker sold 100,000 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of $10.22, for a total value of $1,022,000.00. Following the sale, the chief operating officer now owns 1,116,345 shares in the company, valued at $11,409,045.90. The trade was a 8.22% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,223,959 shares of company stock worth $13,420,035. 7.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on ROIV shares. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Monday, April 21st.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV traded up $0.03 during midday trading on Friday, reaching $10.79. 3,709,915 shares of the stock traded hands, compared to its average volume of 5,592,074. The stock has a market capitalization of $7.70 billion, a PE ratio of -71.93 and a beta of 1.23. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $13.06. The company's 50 day moving average is $10.51 and its 200 day moving average is $11.08.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.